Welcome to our dedicated page for Regulus Therapeu SEC filings (Ticker: RGLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regulus Therapeutics Inc. (RGLS) SEC filings page provides access to the company’s regulatory documents, which trace its transition from a Nasdaq-listed biopharmaceutical issuer to an indirect wholly owned subsidiary of Novartis AG. Regulus has focused on developing medicines targeting microRNAs, with its lead program farabursen (RGLS8429) for autosomal dominant polycystic kidney disease (ADPKD) prominently discussed in its public reports.
Key filings include a Form 8‑K dated June 25, 2025, in which Regulus reports the completion of the acquisition by Novartis. This filing describes the tender offer for all outstanding shares of common stock, the offer consideration composed of a cash amount per share plus a non-tradeable contingent value right (CVR), and the subsequent merger of a Novartis subsidiary with and into Regulus. The 8‑K details how outstanding shares, stock options, restricted stock units, performance-based awards, and warrants were treated in connection with the transaction, and notes that Regulus became the surviving corporation and an indirect wholly owned subsidiary of Novartis.
For trading status and listing history, a Form 25 filed on June 25, 2025, by The Nasdaq Stock Market LLC notifies the removal of Regulus common stock from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. This document reflects the delisting of the RGLS common stock from Nasdaq following the completion of the merger.
Subsequently, a Form 15 filed on July 7, 2025, certifies the termination of registration of Regulus common stock under Section 12(g) of the Exchange Act and the suspension of the company’s duty to file reports under Sections 13 and 15(d). The Form 15 notes that the approximate number of holders of record as of the certification date was one, consistent with Regulus operating as a wholly owned subsidiary.
These filings, together with earlier periodic and current reports, document Regulus Therapeutics’ regulatory history, its microRNA-focused biopharmaceutical activities, and the corporate steps leading to its acquisition and delisting. On Stock Titan, AI-powered tools can help summarize lengthy forms such as 8‑Ks and related exhibits, highlight how securities and contingent value rights were structured, and clarify the implications of Forms 25 and 15 for the historical RGLS ticker and former public shareholders.
Regulus Therapeutics Inc. (RGLS): Schedule 13G/A disclosure summarizing Point72 filings. Point72 Asset Management, Point72 Capital Advisors Inc. and Steven A. Cohen report beneficial ownership of 241,157 shares, representing 0.3% of the outstanding common stock on a diluted basis. The filing states these shares include shares issuable upon exercise of warrants and that Point72 entities hold shared voting and dispositive power over 241,157 shares with no sole voting or dispositive power. The ownership percentage is calculated using a total of 69,475,246 shares outstanding, which includes the 241,157 warrant shares.
Regulus Therapeutics Inc. is the subject of a Schedule 13G/A filed by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin reporting that none of the reporting persons beneficially own any shares of Regulus common stock. The filing lists 0 shares and 0.00% ownership, with beneficial ownership calculated using an issuer share count of 69,234,089 common shares outstanding.
The reporting persons state the securities were not acquired to influence control of the issuer and that the filing is made on behalf of each undersigned. This disclosure indicates the filers currently hold no economic or voting interest in Regulus and do not represent a change in ownership or control.